Triovix is a combined preparation, containing Lamivudine INN 150mg, Zidovudine USP 300mg & Nevirapine INN 200mg/tablet.
Ind & use: This is a fixed dose combination of lamivudine, zidovudine and nevirapine, recommended for human immunodeficiency virus (HIV-1) infected patients who are able to tolerate standard doses of lamivudine, zidovudine and nevirapine separately for at least 2 weeks prior to switching over to this fixed dose combination. Patients should have demonstrated adequate tolerability to nevirapine i.e who are able to tolerate maintenance therapy with nevirapine 200mg twice daily.
This three-drug combined preparation is administered twice daily and each tablet contains half of the daily dose for each component. Twice daily formulation in single tablet for three drugs is convenient for patients to take and also ensures higher rate of compliance.
C/I: Please see above under the text of lamivudine & zidovudine. For nevirapine- history of hypersensitivity; not to be used as initial therapy, because initial therapy requires 200mg once daily, whereas fixed dose combination allows for 200mg twice daily.
S/E: Please see above under the text of lamivu¬dine & zidovudine. For nevirapine: more ferquent incidence- skin rash, diarrhea, gastrointestinal problems, headache, nausea, stomach pain; less frequent incidence- aphthous stomatitis, fever, hepatitis, Stevens- Johnson syndrome.
Warnings & precautions: For the following conditions, assess risk to the patient and take action as needed- chronic hepatitis B, hepatomegaly with steatosis, lactic acidosis, liver function impairment, severe renal function impairment, peripheral neuropathy.
Dosage & admin: For treatment of HIV infec¬tion: Adult dosage- 1 tablet twice daily.
This fixed dose combination is not recom¬mended for patients who have not been on initial lower dose of nevirapine 200mg once daily for 2 weeks and/or have not tolerated this dose. After successful therapy with low dose nevirapine for two weeks, patients can be switched over to 200mg b.i.d dose provided they have not demonstrated any hypersensitiv¬ity reaction (rash, abnormal liver function tests) during their initial exposure to nevirap¬ine. Monitoring of patients for their liver function tests etc is desirable prior to initiating therapy with nevirapine and monitoring at frequent intervals once therapy with fixed dose combination is continued.
Dosage adjustment: As this is a fixed-dose combination, it should not be prescribed for patients requiring dosage adjustment such as those with reduced renal function (creatinine clearance < 50ml/min), those with low body- weight (50kg or 110 lb), or those experiencing dose-limiting adverse events.
This is also not recommended for patients with impaired hepatic function.
10's pack: 700.00 IP